Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Cardiovascular

Transcatheter aortic valve implantation for patients with symptomatic severe native aortic stenosis

27 March 2026

Published on 29 Sep 2021
Last Updated on 27 Mar 2026

Technology Guidance issued by the Agency for Care Effectiveness based on assessments made by the MOH Medical Technology Advisory Committee and recommendations of the Health Technology Advisory Council

Guidance Recommendation

Transcatheter aortic valve implantation (TAVI) is recommended for inclusion on the MOH Implant Subsidy List (ISL) for treatment of patients with symptomatic severe native aortic stenosis (AS) in line with the following criteria:

  • TAVI may be considered for patients with symptomatic severe native AS who are inoperable or at high risk of mortality from surgical aortic valve replacement (SAVR) surgery and significant comorbidities.

  • Patient selection should be carried out by a multidisciplinary heart team, which must at minimum include an interventional cardiologist and a cardiac surgeon. The team should determine the surgical mortality risk for each patient based on:

    • An estimated mortality risk of 8% or greater within 30 days of surgery, according to the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) risk assessment; OR

    • Other patient characteristics where these conditions are clinically equivalent to inoperable or high risk (STS-PROM score ≥8%). These examples could include but are not limited to those listed in the Annex. Where appropriate, objective tools should be used to assess these characteristics.

  • TAVI should be conducted by a multidisciplinary heart team that has met the applicable TAVI training and accreditation standards set by the institution.

  • The TAVI procedure should be performed via transfemoral delivery, unless it is contraindicated or not feasible, in catheterisation labs or hybrid operating theatres equipped with early in-hospital access to cardiac and vascular surgical support for the emergency treatment of complications and subsequent patient care.

  • Properly record details of final surgical risk assessments of all patients who receive TAVI including STS-PROM score, type of TAVI device and clinical outcomes. This is consistent with the standard arrangements in place for clinical governance and audit.

  • TAVI should not be subsidised if the patient has received a prior SAVR or TAVI implant.

Funding status

Listed models on MOH ISL are recommended for subsidy when used in line with the abovementioned recommendations.

Transcatheter aortic valve implementation for patients with symptomatic severe native aortic stenosis (Published 27 Mar 2026)

Back to top